Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.

[1]  E. Topol,et al.  Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.

[2]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[3]  T. Forst,et al.  Influence of Glucose Control and Improvement of Insulin Resistance on Microvascular Blood Flow and Endothelial Function in Patients with Diabetes Mellitus Type 2 , 2005, Microcirculation.

[4]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[5]  Y. Aso,et al.  Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. , 2005, Diabetes care.

[6]  W. Koenig,et al.  Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Nikolaus Marx,et al.  Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. , 2005, Journal of the American College of Cardiology.

[8]  T. Forst,et al.  Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study , 2005, Circulation.

[9]  E. Schaefer,et al.  Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. , 2005, The American journal of cardiology.

[10]  E. Tuzcu,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease , 2005 .

[11]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[12]  R. Krauss,et al.  Diagnosis and management of the metabolic syndrome , 2005 .

[13]  K. Koh,et al.  Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. , 2004, International journal of cardiology.

[14]  V. Fuster,et al.  C-reactive protein and coronary heart disease. , 2004, The New England journal of medicine.

[15]  S. Devaraj,et al.  C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis? , 2004, Hypertension.

[16]  A. Aljada,et al.  Evidence for a potent antiinflammatory effect of rosiglitazone. , 2004, The Journal of clinical endocrinology and metabolism.

[17]  M. Akın,et al.  Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. , 2004, Kardiologia polska.

[18]  H. Markus,et al.  Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[20]  C. Meisinger,et al.  C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany , 2004, Circulation.

[21]  M. Hanefeld,et al.  In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. , 2004, Diabetes care.

[22]  K. Tanabe,et al.  Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. , 2003, American heart journal.

[23]  W. Koenig,et al.  Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease , 2003, Circulation.

[24]  Erik Jørgensen,et al.  Low restenosis rate of the NIR coronary stent: results of the Danish multicenter stent study (DANSTENT)--a randomized trial comparing a first-generation stent with a second-generation stent. , 2003, American heart journal.

[25]  W. Koenig,et al.  Antidiabetic PPAR&ggr;-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease , 2003 .

[26]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[27]  D. Lefer.  Statins as potent antiinflammatory drugs. , 2002, Circulation.

[28]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[29]  A. Naylor,et al.  Matrix metalloproteinases and atherosclerotic plaque instability , 2002, The British journal of surgery.

[30]  M. Matsuda,et al.  Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. , 2002, Diabetes care.

[31]  V. Fuster,et al.  Inflammatory markers in coronary artery disease: let prevention douse the flames. , 2001, JAMA.

[32]  M. Matsuda,et al.  Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.

[33]  U. Ikeda,et al.  Fluvastatin Inhibits Matrix Metalloproteinase-1 Expression in Human Vascular Endothelial Cells , 2000, Hypertension.

[34]  S. Tanaka,et al.  Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. , 2000, The Journal of clinical endocrinology and metabolism.

[35]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[36]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[37]  Hiroyuki Tanaka,et al.  A986S polymorphism of calcium-sensing receptor , 1999, The Lancet.

[38]  U. Ikeda,et al.  Statins and C-reactive protein , 1999, The Lancet.

[39]  T. Strandberg,et al.  Effect of statins on C-reactive protein in patients with coronary artery disease , 1999, The Lancet.

[40]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[41]  F. Bernini,et al.  HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[42]  T. Ueno,et al.  Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. , 1998, Journal of the American College of Cardiology.

[43]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[44]  P. Libby,et al.  Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. , 1998, The American journal of medicine.

[45]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[46]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[47]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[48]  H. Buchwald,et al.  Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). , 1995, Journal of the American College of Cardiology.